Oral Lichen Planus Successfully Treated With Upadacitinib
Journal of Drugs in Dermatology · 2024
DOI: 10.36849/jdd.7859 ↗At a glance
Fallbericht in Journal of Drugs in Dermatology, 2024. Written by Kristin Slater and 2 co-authors. Major MEDLINE topics: Lichen Planus, Oral, Janus Kinase Inhibitors. Cited 14 times so far (Crossref).
Abstract (original language)
With the rise of Janus kinase (JAK) and Signal Transducer and Activator of Transcription (STAT) inhibitor use in dermatologic conditions, there has been increasing hope in treating extensive and difficult-to-treat inflammatory cutaneous conditions. Today we report a case of oral lichen planus successfully treated with an oral JAK1 inhibitor, upadacitinib. This case had been unresponsive by several standard methods but responded with 70% improvement within 1 month when treated with upadacitinib. J Drugs Dermatol. 2024;23(4):7859. doi:10.36849/JDD.7859e .
Subjects
MeSH terms (MEDLINE)
Substances
Cite
APA
Slater, K., Halash, K., & Kartono, F. (2024). Oral Lichen Planus Successfully Treated With Upadacitinib. Journal of Drugs in Dermatology. https://doi.org/10.36849/jdd.7859
Vancouver
Slater K, Halash K, Kartono F. Oral Lichen Planus Successfully Treated With Upadacitinib. Journal of Drugs in Dermatology. 2024. doi:10.36849/jdd.7859
BibTeX
@article{Slater2024,
author = {Slater, Kristin and Halash, Katelyn and Kartono, Francisca},
title = {Oral Lichen Planus Successfully Treated With Upadacitinib},
journal = {Journal of Drugs in Dermatology},
year = {2024},
doi = {10.36849/jdd.7859}
}
EUVIMED